Rheumatology CME

Maximize your CME allowance with MDCalc and get up to a $3,500 bonus gift card of your choice. Earn AMA PRA Category 1 Credits^TM for clinical content on 150+ calculators across multiple medical specialties. Easily earn and redeem CME at the point-of-care, online on our website or mobile app. Over 1 million medical professionals use MDCalc’s 550+ tools daily to support clinical decision making at the bedside.

On-the-go Audio CME: Learn from the Experts

With its comprehensive coverage of all 16 ACP MKSAP topic areas, our all-new ACP MKSAP^SM Audio Companion keeps you engaged with fascinating discussions led by renowned contributors and section editors, breaking down the latest advances in a format designed for active listening.

Rheumatology CME: Expand Your Knowledge

The Brigham Board Review and Comprehensive Update in Rheumatology is designed to improve overall knowledge and clinical competency with comprehensive updates on basic principles, changing guidelines and therapeutic strategies. In this convenient online CME program, world-renowned faculty — led by Jonathan S. Coblyn, MD, Paul F. Dellaripa, MD, and Simon M. Helfgott, MD — cover key rheumatologic medicine topic areas, including:

• Rheumatoid arthritis
• SLE and antiphospholipid AB syndrome
• Sjögren’s and MCTD
• Psoriatic arthritis and other spondyloarthropathies
• Regional pain/sports medicine
• Inflammatory myositis and other myopathies
• Infectious, rheumatologic, and systemic diseases
• and more…

Updates in Primary Immunodeficiency provides an educational forum for in-depth reviews of common and rare inborn errors of immunity (IEI). Cleveland Clinic’s expert faculty discusses this group of more than 400 complex, chronic disorders, and provides insight on developing diagnostics, therapies and advances in treatment. Healthcare practitioners with an interest in allergy, immunology, rheumatology, hematology and more will all benefit from the didactic lectures and cases presented throughout this comprehensive activity. Worth 10 AMA PRA Category I Credits™ applicable to American Board of Allergy and Immunology Continuing Certification. ANCC and AAPA accreditation provided as well!

Stay on top of your game with the StatPearls Physician Unlimited CME programs. With 6,046 activities, StatPearls is the largest CME provider in the world. These Pub-Med Indexed articles are categorized into 162 specialty areas which lets you better access activities that will make the biggest impact on your practice. One subscription allows access to all the activities, including all state-requirements.

Pricing Options

• 6 Month subscription: All 6,339 CME Activities – $249 per 6 months
• Annual subscription: All 6,339 CME Activities – $349 per 1 year
• Lifetime: All 6,339 CME Activities + Access to Board Reviews Forever – $1999

The course introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are also provided.

CBD in Clinical Care provides information that will assist clinicians in effectively treating and counseling cannabidiol (CBD) consumers. The physiological effects of CBD, CBD drug interactions, CBD’s side effects, and the conditions for which CBD has been shown by evidence-based clinical studies to be efficacious are all discussed in this course.

The New York Medical Cannabis Program Required Course Bundle has been approved by the New York State Office of Cannabis Management and satisfies the New York educational requirements to become a practitioner with the New York Medical Cannabis Program.

This bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

The New York State Medical Cannabis Program Rules and Regulations are outlined in a state-specific course, as well.

The Ohio Healthcare Provider Medical Marijuana Course Bundle for Certification (or maintenance of the CTR) is certified by the Ohio State Medical Association and satisfies the CME requirements for the initial Ohio Certificate to Recommend (CTR) application or for maintenance of the CTR.

This bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

The Ohio Medical Marijuana Control Program rules and regulations are outlined in a state-specific course, as well.

The Pennsylvania Medical Marijuana Program Required Course Bundle has been approved by the Pennsylvania Department of Health and satisfies the Pennsylvania educational requirements to become a practitioner with the Pennsylvania Medical Marijuana Program.

This bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

This course bundle also addresses the use of cannabidiol (CBD) in clinical care, and the information will assist clinicians in effectively treating and counseling CBD consumers. The physiological effects of CBD, CBD drug interactions, CBD’s side effects, and the conditions for which CBD has been shown by evidence-based clinical studies to be efficacious are all discussed in this course bundle.

The Pennsylvania Medical Marijuana Program rules and regulations are outlined in a state-specific course, as well.

The Utah Medical Cannabis Program Required Course Bundle has been approved by the Utah Department of Health and satisfies the Utah educational requirements to become a practitioner with the Utah Medical Cannabis Program.

The Utah Medical Cannabis Program Required Course Bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

This course bundle also provides information that assists clinicians in effectively treating and counseling CBD consumers.

The West Virginia Medical Cannabis Program Required Course Bundle has been approved by the West Virginia Department of Health and Human Resources, Bureau for Public Health, Office of Medical Cannabis and satisfies the West Virginia educational requirements to become a practitioner with the West Virginia Medical Cannabis Program.

This course introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

This course bundle also addresses the use of cannabidiol (CBD) in clinical care, and the information will assist clinicians in effectively treating and counseling CBD consumers. The physiological effects of CBD, CBD drug interactions, CBD’s side effects, and the conditions for which CBD has been shown by evidence-based clinical studies to be efficacious are all discussed in this course bundle.

The West Virginia medical cannabis program rules and regulations are outlined in a state-specific course, as well.

The West Virginia medical cannabis program rules and regulations are outlined in a state-specific course, as well.

In this online, self-learning activity:

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), affecting over 40% of patients with lupus. It is a major contributor to morbidity, healthcare utilization, and progression to end-stage renal disease (ESRD). The prevalence of LN has increased significantly over time, from 16.8 per 100,000 in 1985 to 21.2 per 100,000 more recently. The mortality rate associated with LN remains high with a standardized mortality ratio of 6.33 compared to the general population. Despite increased advances in treatments, long-term survival rates have not improved significantly over the past four decades. The 10-year survival rate is around 70%, while the incidence of progression in ESRD in LN patients affects up to 13% of patients over time.